MicroRNAs: New players in IBD

Gut

Volumn 64, Issue 3, 2015, Pages 504-517

  Kalla, R ^a   Ventham, N T ^a   Kennedy, N A ^a   Quintana, J F ^a   Nimmo, E R ^a   Buck, A H ^a   Satsangi, J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; BIOLOGICAL MARKER; CASPASE RECRUITMENT DOMAIN PROTEIN 15; M PROTEIN; MEMBRANE PROTEIN; MICRORNA; MICRORNA 10A; MICRORNA 122; MICRORNA 124; MICRORNA 127; MICRORNA 141; MICRORNA 146A; MICRORNA 155; MICRORNA 17 5P; MICRORNA 181; MICRORNA 192; MICRORNA 19B; MICRORNA 200B; MICRORNA 21; MICRORNA 210; MICRORNA 24; MICRORNA 29; MICRORNA 30C; MICRORNA 326; MICRORNA 629; MICRORNA 7; MIRAVIRSEN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN ATG16L1; UNCLASSIFIED DRUG; UNINDEXED DRUG; GENETIC MARKER;

ADAPTIVE IMMUNITY; ARTICLE; AUTOPHAGY; BIOGENESIS; CELL DIFFERENTIATION; COLITIS; CROHN DISEASE; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; EPIGENETICS; EPITHELIAL BARRIER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PERMEABILITY BARRIER; REGULATORY T LYMPHOCYTE; RNA GENE; RNA PROCESSING; RNA TRANSLATION; SIGNAL TRANSDUCTION; TH17 CELL; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; PHYSIOLOGY;

ADAPTIVE IMMUNITY; EPIGENESIS, GENETIC; GENETIC MARKERS; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; MICRORNAS;

EID: 84922354753     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307891     Document Type: Article

References (207)

1. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322-37.
2. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24.
3. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12:861-74.
4. Xu W-D, Pan H-F, Li J-H, et al. MicroRNA-21 with therapeutic potential in autoimmune diseases. Expert Opin Ther Targets 2013;17:659-65.
5. Shi C, Liang Y, Yang J, et al. MicroRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury. PLoS ONE 2013;8:e66814.
6. Wang Y, Gao X, Wei F, et al. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene 2014;533:389-97.
7. Adams AT, Kennedy NA, Hansen R, et al. Two-stage genome-wide methylation profiling in childhood-onset Crohn's disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci. Inflamm Bowel Dis 2014;20:1784-93.
8. Wu F, Dong F, Arendovich N, et al. Divergent influence of microRNA-21 deletion on murine colitis phenotypes. Inflamm Bowel Dis 2014;20:1972-85.
9. Brain O, Owens BMJ, Pichulik T, et al. The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. Immunity 2013;39:521-36.
10. Brest P, Lapaquette P, Souidi M, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet 2011;43:242-5.
11. Ambros V. A hierarchy of regulatory genes controls a larva-to-adult developmental switch in C. Elegans. Cell 1989;57:49-57.
12. Chalfie M, Horvitz HR, Sulston JE. Mutations that lead to reiterations in the cell lineages of C. Elegans. Cell 1981;24:59-69.
13. Lee RC, Feinbaum RL, Ambros V. The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.
14. Ruvkun G, Giusto J. The Caenorhabditis elegans heterochronic gene lin-14 encodes a nuclear protein that forms a temporal developmental switch. Nature 1989;338:313-19.
15. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-6.
16. Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000;408:86-9.
17. Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34:D140-4.
18. Libri V, Miesen P, van Rij RP, et al. Regulation of microRNA biogenesis and turnover by animals and their viruses. Cell Mol Life Sci 2013;70:3525-44.
19. Ozsolak F, Poling LL, Wang Z, et al. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008;22:3172-83.
20. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA 2007;104:17719-24.
21. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051-60.
22. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006;13:1097-101.
23. Heo I, Ha M, Lim J, et al. Mono-uridylation of pre-microRNA as a key step in the biogenesis of group II let-7 microRNAs. Cell 2012;151:521-32.
24. Han J, Lee Y, Yeom K-H, et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 2006;125:887-901.
25. Han J, Lee Y, Yeom K-H, et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004;18:3016-27.
26. Zeng Y, Cullen BR. Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res 2004;32:4776-85.
27. Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17:3011-16.
28. Lund E, Güttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004;303:95-8.
29. Bernstein E, Caudy AA, Hammond SM, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-6.
30. Gregory RI, Chendrimada TP, Cooch N, et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005;123:631-40.
31. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:1298-307.
32. Chang T-C, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745-52.
33. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-4.
34. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 2008;132:9-14.
35. Zisoulis DG, Kai ZS, Chang RK, et al. Autoregulation of microRNA biogenesis by let-7 and Argonaute. Nature 2012;486:541-4.
36. 0 adenylation mediated by the cytoplasmic poly(A) polymerase GLD-2. Genes Dev 2009;23:433-8.
37. Breving K, Esquela-Kerscher A. The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 2010;42:1316-29.
38. Kawahara Y, Zinshteyn B, Sethupathy P, et al. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science 2007;315:1137-40.
39. Blow MJ, Grocock RJ, van Dongen S, et al. RNA editing of human microRNAs. Genome Biol 2006;7:R27.
40. Yang W, Chendrimada TP, Wang Q, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol 2006;13:13-21.
41. Yeom K-H, Lee Y, Han J, et al. Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids Res 2006;34:4622-9.
42. Han J, Pedersen JS, Kwon SC, et al. Posttranscriptional crossregulation between Drosha and DGCR8. Cell 2009;136:75-84.
43. Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11:228-34.
44. Michlewski G, Guil S, Semple CA, et al. Posttranscriptional regulation of miRNAs harboring conserved terminal loops. Mol Cell 2008;32:383-93.
45. Guil S, Cáceres JF. The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat Struct Mol Biol 2007;14:591-6.
46. Michlewski G, Cáceres JF. Antagonistic role of hnRNP A1 and KSRP in the regulation of let-7a biogenesis. Nat Struct Mol Biol 2010;17:1011-18.
47. Paroo Z, Ye X, Chen S, et al. Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell 2009;139:112-22.
48. Russell AP, Lamon S, Boon H, et al. Regulation of miRNAs in human skeletal muscle following acute endurance exercise and short-term endurance training. J Physiol 2013;591:4637-53.
49. Wan G, Mathur R, Hu X, et al. miRNA response to DNA damage. Trends Biochem Sci 2011;36:478-84.
50. Wan G, Zhang X, Langley RR, et al. DNA-damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway. Cell Rep 2013;3:2100-12.
51. Bhattacharyya SN, Habermacher R, Martine U, et al. Stress-induced reversal of microRNA repression and mRNA P-body localization in human cells. Cold Spring Harb Symp Quant Biol 2006;71:513-21.
52. Kedde M, Agami R. Interplay between microRNAs and RNA-binding proteins determines developmental processes. Cell Cycle 2008;7:899-903. http://www.ncbi.nlm.nih.gov/pubmed/18414021
53. Saunders MA, Liang H, Li W-H. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA 2007;104:3300-5.
54. Tay Y, Zhang J, Thomson AM, et al. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008;455:1124-8.
55. Shin C, Nam J-W, Farh KK-H, et al. Expanding the microRNA targeting code: functional sites with centered pairing. Mol Cell 2010;38:789-802.
56. Helwak A, Kudla G, Dudnakova T, et al. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 2013;153:654-65.
57. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007;318:1931-4.
58. Kim DH, Saetrom P, Snøve O, et al. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci USA 2008;105:16230-5.
59. Friedman RC, Farh KK-H, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
60. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012;19:586-93.
61. Arvey A, Larsson E, Sander C, et al. Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol 2010;6:363.
62. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17.
63. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5.
64. Peterson SM, Thompson JA, Ufkin ML, et al. Common features of microRNA target prediction tools. Front Genet 2014;5:23.
65. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10:126-39.
66. Tsang J, Zhu J, van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell 2007;26:753-67.
67. Milo R, Shen-Orr S, Itzkovitz S, et al. Network motifs: simple building blocks of complex networks. Science 2002;298:824-7.
68. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43.
69. Shen-Orr SS, Milo R, Mangan S, et al. Network motifs in the transcriptional regulation network of Escherichia coli. Nat Genet 2002;31:64-8.
70. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693-706.
71. Hatziapostolou M, Polytarchou C, Aggelidou E, et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011;147:1233-47.
72. Herranz H, Cohen SM. MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems. Genes Dev 2010;24:1339-44.
73. Mannaerts I, Eysackers N, Onyema OO, et al. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS ONE 2013;8: e55786.
74. Miao C, Yang Y, He X, et al. New advances of microRNAs in the pathogenesis of rheumatoid arthritis, with a focus on the crosstalk between DNA methylation and the microRNA machinery. Cell Signal 2013;25:1118-25.
75. Suzuki H, Takatsuka S, Akashi H, et al. Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res 2011;71:5646-58.
76. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013;495:384-8.
77. Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013;145:293-308.
78. Dai E, Yu X, Zhang Y, et al. EpimiR: a database of curated mutual regulation between miRNAs and epigenetic modifications. Database (Oxford) 2014;2014: bau023.
79. Wang LQ, Liang R, Chim CS. Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. Expert Rev Mol Diagn 2012;12:755-65.
80. Zhang Y, Wang X, Xu B, et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep 2013;30:1976-84.
81. Suzuki R, Yamamoto E, Nojima M, et al. Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol 2013;49:1135-44.
82. Han L, Witmer PD, Casey E, et al. DNA methylation regulates MicroRNA expression. Cancer Biol Ther 2007;6:1284-8.
83. Pan C, Chen H, Wang L, et al. Down-regulation of MiR-127 facilitates hepatocyte proliferation during rat liver regeneration. PLoS ONE 2012;7:e39151.
84. Escobar TM, Kanellopoulou C, Kugler DG, et al. miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. Immunity 2014;40:865-79.
85. Salzman J, Gawad C, Wang PL, et al. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE 2012;7:e30733.
86. Chen C-Z, Schaffert S, Fragoso R, et al. Regulation of immune responses and tolerance: the microRNA perspective. Immunol Rev 2013;253:112-28.
87. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009;136:26-36.
88. Geremia A, Biancheri P, Allan P, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014;13:3-10.
89. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002;122:867-74.
90. Chen Y, Wang C, Liu Y, et al. miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn's disease. Biochem Biophys Res Commun 2013;438:133-9.
91. Ghorpade DS, Sinha AY, Holla S, et al. NOD2-nitric oxide-responsive microRNA-146a activates Sonic hedgehog signaling to orchestrate inflammatory responses in murine model of inflammatory bowel disease. J Biol Chem 2013;288:33037-48.
92. Chuang AY, Chuang JC, Zhai Z, et al. NOD2 expression is regulated by microRNAs in colonic epithelial HCT116 cells. Inflamm Bowel Dis 2014;20:126-35.
93. He X, Jing Z, Cheng G. MicroRNAs: new regulators of Toll-like receptor signalling pathways. Biomed Res Int 2014;2014:945169.
94. Thai T-H, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science 2007;316:604-8.
95. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011;208:1189-201.
96. Taganov KD, Boldin MP, Chang K-J, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006;103:12481-6.
97. Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA 2009;106:2735-40.
98. O'Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007;104:1604-9.
99. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007;316:608-11.
100. Lu L-F, Thai T-H, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009;30:80-91.
101. Xu C, Ren G, Cao G, et al. miR-155 regulates immune modulatory properties of mesenchymal stem cells by targeting TAK1-binding protein 2. J Biol Chem 2013;288:11074-9.
102. Schulte LN, Westermann AJ, Vogel J. Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing. Nucleic Acids Res 2013;41:542-53.
103. Mazumder A, Bose M, Chakraborty A, et al. A transient reversal of miRNA-mediated repression controls macrophage activation. EMBO Rep 2013;14:1008-16.
104. Androulidaki A, Iliopoulos D, Arranz A, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009;31:220-31.
105. Chen X-M, Splinter PL, O'Hara SP, et al. A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem 2007;282:28929-38.
106. Zhou X, Li X, Ye Y, et al. MicroRNA-302b augments host defense to bacteria by regulating inflammatory responses via feedback to TLR/IRAK4 circuits. Nat Commun 2014;5:3619.
107. Ma C, Li Y, Li M, et al. microRNA-124 negatively regulates TLR signaling in alveolar macrophages in response to mycobacterial infection. Mol Immunol 2014;62:150-8.
108. Qi J, Qiao Y, Wang P, et al. microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-KB1 in murine macrophages. FEBS Lett 2012;586:1201-7.
109. Bazzoni F, Rossato M, Fabbri M, et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci USA 2009;106:5282-7.
110. Li Q-J, Chau J, Ebert PJR, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007;129:147-61.
111. Li G, Yu M, Lee W-W, et al. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med 2012;18: 1518-24.
112. Guerau-de-Arellano M, Smith KM, Godlewski J, et al. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 2011;134:3578-89.
113. Lu L-F, Boldin MP, Chaudhry A, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010;142:914-29.
114. Steiner DF, Thomas MF, Hu JK, et al. MicroRNA-29 regulates T-box transcription factors and interferon-γ production in helper T cells. Immunity 2011;35:169-81.
115. Banerjee A, Schambach F, DeJong CS, et al. Micro-RNA-155 inhibits FN-gamma signaling in CD4+ T cells. Eur J Immunol 2010;40:225-31.
116. Jiang S, Li C, Olive V, et al. Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 2011;118:5487-97.
117. Sawant DV, Wu H, Kaplan MH, et al. The Bcl6 target gene microRNA-21 promotes Th2 differentiation by a T cell intrinsic pathway. Mol Immunol 2013;54:435-42.
118. Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009;10:1252-9.
119. Takahashi H, Kanno T, Nakayamada S, et al. TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. Nat Immunol 2012;13:587-95.
120. Mycko MP, Cichalewska M, Machlanska A, et al. MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc Natl Acad Sci USA 2012;109:E1248-57.
121. O'Connell RM, Kahn D, Gibson WSJ, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33:607-19.
122. Murugaiyan G, Beynon V, Mittal A, et al. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2011;187:2213-21.
123. Singh UP, Murphy AE, Enos RT, et al. miR-155 deficiency protects mice from experimental colitis by reducing Th1/Th17 responses. Immunology 2014;143:478-89.
124. Wang H, Flach H, Onizawa M, et al. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol 2014;15:393-401.
125. Jeker LT, Zhou X, Gershberg K, et al. MicroRNA 10a marks regulatory T cells. PLoS ONE 2012;7:e36684.
126. De Kouchkovsky D, Esensten JH, Rosenthal WL, et al. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol 2013;191:1594-605.
127. Koralov SB, Muljo SA, Galler GR, et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008;132:860-74.
128. Fazilleau N, Mark L, McHeyzer-Williams LJ, et al. Follicular helper T cells: lineage and location. Immunity 2009;30:324-35.
129. Kang SG, Liu W-H, Lu P, et al. MicroRNAs of the miR-17~92 family are critical regulators of T(FH) differentiation. Nat Immunol 2013;14:849-57.
130. Chen C-Z, Li L, Lodish HF, et al. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-6.
131. Li X, Zhang J, Gao L, et al. MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death Differ 2012;19:378-86.
132. Muljo SA, Ansel KM, Kanellopoulou C, et al. Aberrant T cell differentiation in the absence of Dicer. J Exp Med 2005;202:261-9.
133. Chong MMW, Rasmussen JP, Rudensky AY, et al. The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med 2008;205:2005-17.
134. Troncone E, Marafini I, Pallone F, et al. Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad. Int Rev Immunol 2013;32:526-33.
135. Cobb BS, Hertweck A, Smith J, et al. A role for Dicer in immune regulation. J Exp Med 2006;203:2519-27.
136. Zhou X, Jeker LT, Fife BT, et al. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 2008;205:1983-91.
137. Van Rooij E. The art of microRNA research. Circ Res 2011;108:219-34.
138. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
139. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008;14:844-52.
140. Rahmann S, Martin M, Schulte JH, et al. Identifying transcriptional miRNA biomarkers by integrating high-throughput sequencing and real-time PCR data. Methods 2013;59:154-63.
141. Garmire LX, Subramaniam S. Evaluation of normalization methods in mammalian microRNA-Seq data. RNA 2012;18:1279-88.
142. Drong AW, Lindgren CM, McCarthy MI. The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 2012;92:707-15.
143. Rakyan VK, Down TA, Balding DJ, et al. Epigenome-wide association studies for common human diseases. Nat Rev Genet 2011;12:529-41.
144. Thu Nguyen HT, Dalmasso G, Müller S, et al. Crohn's disease-associated adherent invasive Escherichia coli affect levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology 2013;146:508-19.
145. Zhai Z, Wu F, Dong F, et al. Human autophagy gene ATG16L1 is post-transcriptionally regulated by MIR142-3p. Autophagy 2014;10:468-79.
146. Lu C, Chen J, Xu H-G, et al. MIR106B and MIR93 prevent removal of bacteria from epithelial cells by disrupting ATG16L1-mediated autophagy. Gastroenterology 2014;146:188-99.
147. Xue X, Feng T, Yao S, et al. Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40. J Immunol 2011;187:5879-86.
148. Koukos G, Polytarchou C, Kaplan JL, et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology 2013;145:842-52.e2.
149. Yang Y, Ma Y, Shi C, et al. Overexpression of miR-21 in patients with ulcerative colitis impairs intestinal epithelial barrier function through targeting the Rho GTPase RhoB. Biochem Biophys Res Commun 2013;434:746-52.
150. Nata T, Fujiya M, Ueno N, et al. MicroRNA-146b improves intestinal injury in mouse colitis by activating nuclear factor-KB and improving epithelial barrier function. J Gene Med 2013;15:249-60.
151. Chen Y, Xiao Y, Ge W, et al. miR-200b inhibits TGF-β1-induced epithelial-mesenchymal transition and promotes growth of intestinal epithelial cells. Cell Death Dis 2013;4:e541.
152. Feng X, Wang H, Ye S, et al. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBCα. PLoS ONE 2012;7:e52782.
153. Nguyen HTT, Dalmasso G, Yan Y, et al. MicroRNA-7 modulates CD98 expression during intestinal epithelial cell differentiation. J Biol Chem 2010;285:1479-89.
154. Mizushima N, Yoshimori T, Ohsumi Y. Role of the Apg12 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 2003;35:553-61.
155. Henderson P, Wilson DC, Satsangi J, et al. A role for vimentin in Crohn disease. Autophagy 2012;8:1695-6.
156. Wan G, Xie W, Liu Z, et al. Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy 2014;10:70-9.
157. Füllgrabe J, Klionsky DJ, Joseph B. The return of the nucleus: transcriptional and epigenetic control of autophagy. Nat Rev Mol Cell Biol 2014;15:65-74.
158. Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-25.
159. Gibbings D, Mostowy S, Jay F, et al. Selective autophagy degrades DICER and AGO2 and regulates miRNA activity. Nat Cell Biol 2012;14:1314-21.
160. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene RGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-2.
161. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604.
162. Boone DL, Lee EG, Libby S, et al. Recent advances in understanding NF-kappaB regulation. Inflamm Bowel Dis 2002;8:201-12.
163. Maharshak N, Shenhar-Tsarfaty S, Aroyo N, et al. MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1346-53.
164. Shaked I, Meerson A, Wolf Y, et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 2009;31:965-73.
165. Pastorelli L, De Salvo C, Mercado JR, et al. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 2013;4:280.
166. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-52.
167. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
168. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
169. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
170. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-18.
171. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-41.
172. Chim SSC, Shing TKF, Hung ECW, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008;54:482-90.
173. Zheng H, Liu J-Y, Song F-J, et al. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med 2013;10:123-30.
174. Rao P, Benito E, Fischer A. MicroRNAs as biomarkers for CNS disease. Front Mol Neurosci 2013;6:39.
175. Kinet V, Halkein J, Dirkx E, et al. Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-to-cell RNA communication. Front Genet 2013;4:214.
176. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012;5:492-7.
177. Haider BA, Baras AS, McCall MN, et al. A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS ONE 2014;9:e89565.
178. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010;70:7027-30.
179. Huang Z, Shi T, Zhou Q, et al. miR-141 Regulates colonic leukocytic trafficking by targeting CXCL12β during murine colitis and human Crohn's disease. Gut 2014;63:1247-57.
180. Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685-94.
181. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735-9.
182. Wienholds E, Kloosterman WP, Miska E, et al. MicroRNA expression in zebrafish embryonic development. Science 2005;309:310-11.
183. Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577-81.
184. 0 UTR. Proc Natl Acad Sci USA 2011;108:4991-6.
185. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-65.
186. Van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014;6:851-64.
187. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;132:875-86.
188. Miska EA, Alvarez-Saavedra E, Abbott AL, et al. Most Caenorhabditis elegans microRNAs are individually not essential for development or viability. PLoS Genet 2007;3:e215.
189. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456: 980-4.
190. Thum T, Chau N, Bhat B, et al. Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J Clin Invest 2011;121:461-2; author reply 462-3.
191. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012;148:1172-87.
192. Leung AKL, Sharp PA. MicroRNA functions in stress responses. Mol Cell 2010;40:205-15.
193. Huse JT, Brennan C, Hambardzumyan D, et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009;23:1327-37.
194. Pecot CV, Calin GA, Coleman RL, et al. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011;11:59-67.
195. De Pontual L, Yao E, Callier P, et al. Germline deletion of the miR-17~92 cluster causes skeletal and growth defects in humans. Nat Genet 2011;43:1026-30.
196. Hsu S-H, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012;122:2871-83.
197. Tsai W-C, Hsu S-D, Hsu C-S, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012;122:2884-97.
198. Schwarz DS, Hutvágner G, Du T, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115:199-208.
199. Schwarz DS, Hutvágner G, Haley B, et al. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell 2002;10:537-48.
200. Peacock H, Fucini RV, Jayalath P, et al. Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA. J Am Chem Soc 2011;133:9200-3.
201. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19:1116-22.
202. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013;31:577.
203. Miyazaki Y, Adachi H, Katsuno M, et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med 2012;18:1136-41.
204. Deng X, Cao M, Zhang J, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 2014;35:4333-44.
205. Hatakeyama H, Murata M, Sato Y, et al. The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J Control Release 2014;173:43-50.
206. Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011;29:341-5.
207. Ohno S, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 2013;21: 185-91.